Skip to Content

Generic ProAir RespiClick Availability

ProAir RespiClick is a brand name of albuterol, approved by the FDA in the following formulation(s):

PROAIR RESPICLICK (albuterol sulfate - powder, metered;inhalation)

  • Manufacturer: TEVA BRANDED PHARM
    Approval date: March 31, 2015
    Strength(s): EQ 0.090MG BASE/INH [RLD]

Has a generic version of ProAir RespiClick been approved?

No. There is currently no therapeutically equivalent version of ProAir RespiClick available in the United States.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of ProAir RespiClick. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

  • Inhaler dose counter
    Patent 6,446,627
    Issued: September 10, 2002
    Inventor(s): Nicholas John; Bowman & Michael John; Holroyd & Costaninos; Panayi & William Richard; Treneman
    Assignee(s): Norton Healthcare Limited
    A dose counter for a metered dose inhaler comprises actuator means (341), drive means (350) for driving a rotary gear (360) in step-wise fashion in response to displacement of said actuator means (341), said rotary gear (360) comprising a wheel having a plurality of ratchet teeth (not shown) around its periphery. Means (364) are provided to prevent reverse rotation of the rotary gear (360). A flexible tape (368) is provided with a visible array of incrementing integers on its surface indicating the number of medicament doses remaining in the inhaler. The tape (368) indexes by a single integer in response to each step of the step-wise rotary motion of the rotary gear (360). A control surface (371) regulates the position of engagement and disengagement between the drive means (350) and the rotary gear (360). In an alternative embodiment (FIG. 6), the control surface (371) is omitted and the means for preventing reverse rotation comprise a stepless restraint (664).
    Patent expiration dates:
    • December 18, 2017
      ✓ 
      Drug product
  • Dose counter for medicament inhaler
    Patent 6,701,917
    Issued: March 9, 2004
    Inventor(s): David; O'Leary
    Assignee(s): Norton Healthcare, Ltd.
    A new and improved inhaler includes an accurate and consistent mechanical dose metering system that dispenses dry powdered medicament in discrete amounts or doses for patient inhalation, a pressure relief system that manages pressure within a medicament reservoir of the inhaler to ensure consistently dispensed doses, and a dose counting system indicating the number of doses remaining in the inhaler.
    Patent expiration dates:
    • June 23, 2021
      ✓ 
      Drug product
  • Dose metering system for medicament inhaler
    Patent 6,718,972
    Issued: April 13, 2004
    Inventor(s): David; O'Leary
    Assignee(s): IVAX Corporation
    A new and improved inhaler includes an accurate and consistent mechanical dose metering system that dispenses dry powdered medicament in discrete amounts or doses for patient inhalation, a pressure relief system that manages pressure within a medicament reservoir of the inhaler to ensure consistently dispensed doses, and a dose counting system indicating the number of doses remaining in the inhaler.
    Patent expiration dates:
    • June 23, 2021
      ✓ 
      Drug product
  • De-agglomerator for breath-actuated dry powder inhaler
    Patent 6,748,947
    Issued: June 15, 2004
    Inventor(s): Laurence; Keane & David; O'Leary
    Assignee(s): Norton Healthcare, Ltd.
    A de-agglomerator is provided for use with a breath-actuated dry powder inhaler for breaking up aggregates and micronizing particles of dry powder prior to inhalation of the powder by a patient using the inhaler. The de-agglomerator includes an inner wall defining a swirl chamber extending along an axis from a first end to a second end, a dry powder supply port, an inlet port, and an outlet port. The supply port is in the first end of the swirl chamber for providing fluid communication between a dry powder delivery passageway of an inhaler and the first end of the swirl chamber. The inlet port is in the inner wall of the swirl chamber adjacent to the first end of the swirl chamber and provides fluid communication between a region exterior to the de-agglomerator and the swirl chamber. The outlet port provides fluid communication between the second end of the swirl chamber and a region exterior to the de-agglomerator, whereby a breath induced low pressure at the outlet port causes air flows into the swirl chamber through the dry powder supply port and the inlet port. The air flows collide with each other and with the wall of the swirl chamber prior to exiting through the outlet port, such that any powder entrained in the air flows is broken down and micronized. The de-agglomerator further includes vanes at the first end of the swirl chamber for creating additional collisions and impacts of entrained powder.
    Patent expiration dates:
    • June 23, 2021
      ✓ 
      Drug product
  • De-agglomerator for breath-actuated dry powder inhaler
    Patent 6,871,646
    Issued: March 29, 2005
    Inventor(s): Keane; Laurence & O'Leary; David
    Assignee(s): Norton Healthcare Ltd.
    A de-agglomerator is provided for use with a breath-actuated dry powder inhaler for breaking up aggregates and micronizing particles of dry powder prior to inhalation of the powder by a patient using the inhaler. The de-agglomerator includes an inner wall defining a swirl chamber extending along an axis from a first end to a second end, a dry powder supply port, an inlet port, and an outlet port. The supply port is in the first end of the swirl chamber for providing fluid communication between a dry powder delivery passageway of an inhaler and the first end of the swirl chamber. The inlet port is in the inner wall of the swirl chamber adjacent to the first end of the swirl chamber and provides fluid communication between a region exterior to the de-agglomerator and the swirl chamber. The outlet port provides fluid communication between the second end of the swirl chamber and a region exterior to the de-agglomerator, whereby a breath induced low pressure at the outlet port causes air flows into the swirl chamber through the dry powder supply port and the inlet port. The air flows collide with each other and with the wall of the swirl chamber prior to exiting through the outlet port, such that any powder entrained in the air flows is broken down and micronized. The de-agglomerator further includes vanes at the first end of the swirl chamber for creating additional collisions and impacts of entrained powder.
    Patent expiration dates:
    • June 23, 2021
      ✓ 
      Drug product
  • Reservoir pressure system for medicament inhaler
    Patent 7,540,282
    Issued: June 2, 2009
    Inventor(s): O'Leary; David
    Assignee(s): Norton Healthcare Ltd
    An inhaler includes an accurate and consistent mechanical dose metering system that dispenses dry powdered medicament in discrete amounts or doses for patient inhalation, a pressure relief system that manages pressure within a medicament reservoir of the inhaler to ensure consistently dispensed doses, and a dose counting system indicating the number of doses remaining in the inhaler.
    Patent expiration dates:
    • May 6, 2023
      ✓ 
      Drug product
  • Reservoir pressure system for medicament inhaler
    Patent 8,006,690
    Issued: August 30, 2011
    Inventor(s): O'Leary; David
    Assignee(s): Norton Healthcare Ltd
    An inhaler includes an accurate and consistent mechanical dose metering system that dispenses dry powdered medicament in discrete amounts or doses for patient inhalation, a pressure relief system that manages pressure within a medicament reservoir of the inhaler to ensure consistently dispensed doses, and a dose counting system indicating the number of doses dispensed by or remaining in the inhaler.
    Patent expiration dates:
    • June 23, 2021
      ✓ 
      Drug product
  • Dry powder inhalation apparatus
    Patent 8,651,103
    Issued: February 18, 2014
    Assignee(s): Norton Healthcare Ltd.
    The invention relates to dry powder inhalation apparatus usually operable by breath of a user which provides for controlled and smooth transfer of medicament during multiple actuations by a user. A mechanism of the apparatus for achieving this controlled and smooth transfer includes a device (4) normally held adjacent a reservoir for receiving medicament in a cup or receptacle (15) and which is generally movable transversely of a longitudinal axis of the apparatus to delivery channels of the apparatus. This bodily shifting of the device (4) is achieved by a yoke acting on an abutment (16) thereof. Spillage of medicament in the apparatus is avoided.
    Patent expiration dates:
    • March 26, 2028
      ✓ 
      Drug product
  • Dose counters for inhalers, inhalers and methods of assembly thereof
    Patent 8,978,966
    Issued: March 17, 2015
    Assignee(s): Teva Pharmaceuticals Ireland Norton Waterford IVAX Pharmaceuticals Ireland
    A manually operated metered dose inhaler includes a dose counter chamber including a dose display tape driven by a ratchet wheel which is driven in turn by an actuator pawl actuated by movement of a canister, the tape unwinding from a stock bobbin during use of the inhaler, a rotation regulator being provided for the stock bobbin and including a wavelike engagement surface with concavities which engage against control elements in the form of protrusions on resilient forks of a split pin thereby permitting incremental unwinding of the stock bobbin yet resisting excessive rotation if the inhaler is dropped onto a hard surface.
    Patent expiration dates:
    • January 13, 2032
      ✓ 
      Drug product
  • Dose counters for inhalers, inhalers and methods of assembly thereof
    Patent 9,216,260
    Issued: December 22, 2015
    Assignee(s): IVAX Pharmaceuticals Ireland Norton Waterford Teva Pharmaceuticals Ireland
    A manually operated metered dose inhaler includes a dose counter chamber including a dose display tape driven by a ratchet wheel which is driven in turn by an actuator pawl actuated by movement of a canister, the tape unwinding from a stock bobbin during use of the inhaler, a rotation regulator being provided for the stock bobbin and including a wavelike engagement surface with concavities which engage against control elements in the form of protrusions on resilient forks of a split pin thereby permitting incremental unwinding of the stock bobbin yet resisting excessive rotation if the inhaler is dropped onto a hard surface.
    Patent expiration dates:
    • June 28, 2031
      ✓ 
      Drug product
  • Dry powder inhalation apparatus
    Patent 9,463,288
    Issued: October 11, 2016
    Assignee(s): NORTON HEALTHCARE LTD.
    A dry powder inhalation apparatus operable by breath of a user which provides for controlled and smooth transfer of medicament during multiple actuations by a user. A mechanism of the apparatus for achieving this controlled and smooth transfer includes a device normally held adjacent a reservoir for receiving medicament in a cup or receptacle and which is generally movable transversely of a longitudinal axis of the apparatus to delivery channels of the apparatus. This bodily shifting of the device is achieved by a yoke acting on an abutment thereof. Spillage of medicament in the apparatus is avoided.
    Patent expiration dates:
    • May 19, 2025
      ✓ 
      Drug product

Related Exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

  • Exclusivity expiration dates:
    • March 12, 2018 - NEW PRODUCT
    • April 28, 2019 - NEW PATIENT POPULATION

Glossary

TermDefinition
Drug PatentA drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.
Drug ExclusivityExclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.
RLDA Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart.
Hide